A recent comparative effectiveness study examined the cardiovascular risks associated with second-line diabetes therapies in adults with type 2 diabetes. After analyzing data from 48,165 adults, it was found that initiating glipizide therapy post-metformin increased the five-year risk of major adverse cardiovascular events (MACE-4) by 13% compared to dipeptidyl peptidase 4 (DPP4) inhibitors. The study suggests that glipizide may not be suitable for patients at moderate cardiovascular risk, especially older adults, highlighting the need for evaluating individual sulfonylureas in treatment decisions.

Source: JAMA Network Open